(+/-)-N-{4-[1-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-pyridyl)ethyl]phenyl}-N'-ethylurea | 190205-49-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (+/-)-N-{4-[1-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-pyridyl)ethyl]phenyl}-N'-ethylurea
• 英文别名: N-{4-[1-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(pyridin-4-yl)ethyl]phenyl}-N'-ethylurea；(R)-N-(4-(1-(3-Cyclopentyloxy-4-methoxyphenyl)-2-(4-pyridyl)ethyl)phenyl)-N'-ethylurea；1-[4-[1-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyridin-4-ylethyl]phenyl]-3-ethylurea
• CAS: 190205-49-3
• 化学式: C₂₈H₃₃N₃O₃
• 分子量: 459.588
• InChiKey: BRGUNHBITALRGW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  34
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  72.5
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Combination therapies
  申请人：Pfizer Inc

  公开号：US20040209916A1

  公开（公告）日：2004-10-21

  The invention is directed to methods of treating asthma, COPD, allergic rhinitis, and infectious rhinitis by administering a first pharmaceutical agent including one or more compounds selected from the quarternary ammonium compounds of formulae I-V and a second pharmaceutical agent including one or more pharmaceutical agents selected from Adenosine A 2a Receptor Agonists, D2-Dopamine Receptor Agonists, Phosphodiesterase Inhibitors (PDE's), corticosteroids, norepinephrine reuptake inhibitors, 4-hydroxy-7-[2-[2-[3-[2-phenylethoxy]-propylsulphonyl]ethylamino]ethyl]-1,3-benzothiazol-2(3H)-one, and pharmaceutically acceptable salts thereof, and non-quarternized antimuscarinic compounds.

  该发明涉及通过给予包括公式I-V的季铵化合物中选取的一个或多个化合物以及包括选自腺苷A2a受体激动剂、D2-多巴胺受体激动剂、磷酸二酯酶抑制剂（PDE's）、皮质类固醇、去甲肾上腺素再摄取抑制剂、4-羟基-7-[2-[2-[3-[2-苯乙氧基]-丙磺酰乙氨基]-乙基]-1,3-苯并噻唑-2(3H)-酮及其药用可接受的盐以及非季铵化的抗胆碱药物的第二药物，来治疗哮喘、COPD、过敏性鼻炎和感染性鼻炎的方法。
• Methods for the treatment of respiratory diseases and conditions with a selective iNOS inhibitor and a PDE inhibitor and compositions therefor
  申请人：——

  公开号：US20040087653A1

  公开（公告）日：2004-05-06

  Therapeutic methods for the prevention and treatment of respiratory diseases or conditions are described, the methods including administering to a subject in need thereof a respiratory disease or condition effective amount of a selective inhibitor of inducible nitric oxide synthase.

  本文描述了用于预防和治疗呼吸系统疾病或症状的治疗方法，其中的方法包括向需要治疗的对象施用诱导型一氧化氮合酶选择性抑制剂的有效剂量。
• Method for treating or preventing depression
  申请人：——

  公开号：US20010049368A1

  公开（公告）日：2001-12-06

  A neurokinin-1 antagonist or an alpha-2 adrenoreceptor agonist provide an effective therapy in conjunction with a PDE4 inhibitor for the treatment or prevention of depression and/or anxiety. These combinations minimize the side effects of nausea and/or emesis associated with the PDE4 inhibitor and may also provide beneficial antidepressant and/or anti-anxiety effects.

  神经激肽-1拮抗剂或α-2肾上腺素受体激动剂与PDE4抑制剂联用，可有效治疗或预防抑郁症和/或焦虑症。这些组合可将与 PDE4 抑制剂相关的恶心和/或呕吐副作用降至最低，还可提供有益的抗抑郁和/或抗焦虑作用。
• TRI-SUBSTITUTED PHENYL DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS
  申请人：CELLTECH THERAPEUTICS LIMITED

  公开号：EP0626939B1

  公开（公告）日：2001-11-07
• TREATMENT OF DISEASES WITH ALTERED SMOOTH MUSCLE CONTRACTILITY
  申请人：Marx Steven

  公开号：US20120184517A1

  公开（公告）日：2012-07-19

  The present invention provides, inter alia, methods and compositions for treating or ameliorating the effects of a disease characterized by altered smooth muscle contractility, such as e.g., asthma.